down-arrow

Advancing promising early technologies for the treatment of disease from major academic institutions to human proof of concept through accelerated drug discovery.

Bridge Medicines-Accelerating the Path to the Patient

Bridge Medicines is a fully funded, professionally staffed biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. We move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.

how it works

Get to know our experts!

Our Partners

weill-cornell-logo
tri-institutional-logo
takeda-logo.jpg
memorial-sloan-logo
deerfield-logo
bay-city-logo
rockefeller-logo